Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q53742883)
Watch
English
EMA reconsiders 'read-through' drug against Duchenne muscular dystrophy following appeal.
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25101726
retrieved
18 May 2018
reference URL
http://europepmc.org/abstract/MED/25101726
title
EMA reconsiders 'read-through' drug against Duchenne muscular dystrophy following appeal.
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25101726
retrieved
18 May 2018
reference URL
http://europepmc.org/abstract/MED/25101726
main subject
Duchenne muscular dystrophy
1 reference
based on heuristic
inferred from title
author
Asher Mullard
series ordinal
1
object named as
Asher Mullard
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25101726
retrieved
18 May 2018
reference URL
http://europepmc.org/abstract/MED/25101726
publication date
1 August 2014
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25101726
retrieved
18 May 2018
reference URL
http://europepmc.org/abstract/MED/25101726
published in
Nature Biotechnology
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25101726
retrieved
18 May 2018
reference URL
http://europepmc.org/abstract/MED/25101726
volume
32
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25101726
retrieved
18 May 2018
reference URL
http://europepmc.org/abstract/MED/25101726
issue
8
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25101726
retrieved
18 May 2018
reference URL
http://europepmc.org/abstract/MED/25101726
page(s)
706
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25101726
retrieved
18 May 2018
reference URL
http://europepmc.org/abstract/MED/25101726
cites work
Doubts raised over 'read-through' Duchenne drug mechanism
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FNBT0814-706
retrieved
21 January 2018
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FNBT0814-706
retrieved
21 January 2018
Identifiers
DOI
10.1038/NBT0814-706
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25101726
retrieved
18 May 2018
reference URL
http://europepmc.org/abstract/MED/25101726
Dimensions Publication ID
1037083404
0 references
PubMed publication ID
25101726
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25101726
retrieved
18 May 2018
reference URL
http://europepmc.org/abstract/MED/25101726
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
